Defilade Capital Management, L.P. holds a focused book of 31 stocks worth $712.2M as of Q1 2026 (disclosed Jun 12, 2026, a ~45-day 13F lag). This quarter they opened ZIMMER BIOMET HOLDINGS INC and trimmed PFIZER INC. Their largest long position is ZIMMER BIOMET HOLDINGS INC at 7% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2088557/holdings"
Use Arkolith to show Defilade Capital Management, L.P.'s latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
25% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Zimmer Biomet Holdings Inc COM | $52.4M | 579.2K | 7.4% | ▲New New position | |
| 2 | Schein Henry Inc COM | $46.0M | 624.0K | 6.5% | ▲+95% Added · +304K sh | |
| 3 | Becton Dickinson & Co COM | $43.9M | 279.2K | 6.2% | ▲+244% Added · +198K sh | |
| 4 | Pfizer Inc COM | $41.1M | 1.46M | 5.8% | ▼−34% Reduced · −739K sh | |
| 5 | Dexcom Inc COM | $33.8M | 538.8K | 4.8% | ▲+120% Added · +294K sh | |
| 6 | Icu Med Inc COM | $32.8M | 254.3K | 4.6% | ▼−25% Reduced · −86K sh | |
| 7 | Insmed Inc COM PAR $.01 | $31.9M | 194.9K | 4.5% | ▲+290% Added · +145K sh | |
| 8 | Intuitive Surgical Inc COM NEW | $31.2M | 67.7K | 4.4% | ▲+48% Added · +22K sh | |
| 9 | Revolution Medicines Inc COM | $30.7M | 316.0K | 4.3% | ▼−13% Reduced · −47K sh | |
| 10 | Globus Med Inc CL A | $30.5M | 354.4K | 4.3% | ▲+33% Added · +87K sh | |
| 11 | Neurocrine Biosciences Inc COM | $27.7M | 209.9K | 3.9% | ▲New New position | |
| 12 | Denali Therapeutics Inc COM | $26.1M | 1.36M | 3.7% | ▲+107% Added · +703K sh | |
| 13 | PTC Therapeutics Inc COM | $25.6M | 376.2K | 3.6% | ▲New New position | |
| 14 | Olema Pharmaceuticals Inc COM | $22.4M | 1.50M | 3.1% | ▲+22% Added · +270K sh | |
| 15 | Elanco Animal Health Inc COM | $22.3M | 931.1K | 3.1% | ▲+132% Added · +530K sh | |
| 16 | Pacs Group Inc COM SHS | $19.4M | 604.2K | 2.7% | ▼−47% Reduced · −541K sh | |
| 17 | Eli Lilly & Co COM | $19.0M | 20.7K | 2.7% | ▼−35% Reduced · −11K sh | |
| 18 | Lantheus Hldgs Inc COM | $18.9M | 249.4K | 2.7% | ▲New New position | |
| 19 | Integer Hldgs Corp COM | $18.7M | 213.0K | 2.6% | ▲New New position | |
| 20 | Biogen Inc COM | $17.7M | 96.3K | 2.5% | ▼−41% Reduced · −66K sh | |
| 21 | Evommune Inc COM SHS | $15.6M | 678.6K | 2.2% | ▲+215% Added · +463K sh | |
| 22 | Tandem Diabetes Care Inc COM NEW | $14.6M | 761.9K | 2.1% | ▲New New position | |
| 23 | Cogent Biosciences Inc COM | $13.6M | 352.6K | 1.9% | ▼−38% Reduced · −216K sh | |
| 24 | Nuvalent Inc COM | $13.3M | 129.9K | 1.9% | ▼−52% Reduced · −139K sh | |
| 25 | Ocular Therapeutix Inc COM | $12.6M | 1.49M | 1.8% | ▲+118% Added · +806K sh | |
| 26 | Ascendis Pharma A/s SPONSORED ADR | $11.9M | 51.9K | 1.7% | ▼−39% Reduced · −34K sh | |
| 27 | Align Technology Inc COM | $11.5M | 67.3K | 1.6% | ▼−47% Reduced · −61K sh | |
| 28 | Eledon Pharmaceuticals Inc COM | $11.0M | 3.56M | 1.5% | ▲+8.3% Added · +274K sh | |
| 29 | Oric Pharmaceuticals Inc COM | $10.7M | 842.9K | 1.5% | ▲New New position | |
| 30 | Biohaven Ltd COM | $2.7M | 315.9K | 0.4% | ▲New New position | |
| 31 | Mereo Biopharma Group PLC SPON ADS | $2.5M | 7.56M | 0.4% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | Jun 12, 2026 | 31 | $712.2M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 33 | $737.7M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.